Xeris Pharmaceuticals Inc Stock News

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable

Investors need to pay close attention to Xeris Pharmaceuticals (XERS) stock based on the movements in the options market lately.

Meme stocks loved by Reddit traders are on the move today and it's not all rainbows and sunshine as some of them are losing steam. The post Reddit Stocks: What Are Top Meme Stocks AMC, GME and BB Doin

XERS stock could very well be the next stock to get the short squeeze treatment, even without a r/WallStreetBets co-sign. The post Get Ready for a XERS Stock Squeeze!

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Strongbridge

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) and Strongbridge Biopharma plc is fair

NEW YORK, May 24, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Strongbridge Biopharma plc ("Strongb

CHICAGO and DUBLIN and TREVOSE, Pa., May 24, 2021 /PRNewswire/ -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a pharmaceutical company leveraging its novel formulation technology platforms to develo

Xeris Pharmaceuticals recently reported their Q1 earnings with a slight beat on EPS and revenue. Unfortunately, Xeris reported in the middle of the healthcare sell-off and XERS was unjustly punished.

Xeris Pharmaceuticals, Inc.'s (XERS) CEO Paul Edick on Q1 2021 Results - Earnings Call Transcript

New York, New York--(Newsfile Corp. - March 14, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Xeris Pharmaceuticals, Inc. ("Xeris" or the "Company") (NASDAQ: XERS). Such inve

NEW YORK, March 12, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Xeris Pharmaceuticals, Inc. ("Xeris" or the "Company") (NASDAQ: XERS).  Such investors are

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use

NEW YORK, March 10, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Xeris Pharmaceuticals, Inc. ("Xeris" or the "Company") (NASDAQ: XERS).  Such investors are

Xeris Pharmaceuticals, Inc. (XERS) CEO Paul Edick on Q4 2020 Results - Earnings Call Transcript